A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Summary

This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment…

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Systemic Lupus Erythematosus (With and Without Nephritis)
• Idiopathic Inflammatory Myopathy
• Systemic Sclerosis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 74 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Allogene Therapeutics

Last updated on ClinicalTrials.gov

September 10, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites